Skip to product information
1 of 1

Elabscience

SKU:E-AB-F1058M-50Tests

AF647 Anti-Human CD38 Antibody[HIT2]

AF647 Anti-Human CD38 Antibody[HIT2]

Regular price $200.00 USD
Regular price Sale price $200.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
The AF647 Anti-Human CD38 Antibody [HIT2] is a highly specific and reliable tool designed for the detection and analysis of CD38 expression in human samples. This monoclonal antibody is conjugated with AF647, a fluorochrome with excellent photostability and brightness, ensuring accurate and consistent results.

CD38 is a transmembrane glycoprotein that plays a crucial role in various physiological and pathological processes, including immune regulation, cell adhesion, and signal transduction. Its overexpression has been associated with several diseases, making it an important target for research and diagnostic purposes.

The AF647 Anti-Human CD38 Antibody [HIT2] has been extensively validated for flow cytometry applications, enabling the identification and characterization of CD38-positive cells with high sensitivity and specificity. Its exceptional binding affinity ensures minimal background noise, allowing for precise and reliable detection of CD38 expression levels.

This antibody is suitable for use in a wide range of human samples, including peripheral blood, bone marrow, and lymphoid tissues. It is compatible with various flow cytometry platforms and can be used in both research and clinical settings.

The AF647 Anti-Human CD38 Antibody [HIT2] is provided in a convenient format, with each vial containing a predetermined amount of antibody for optimal staining. It is recommended to store the antibody at -20°C to maintain its stability and functionality.

In summary, the AF647 Anti-Human CD38 Antibody [HIT2] is a valuable tool for researchers and clinicians involved in the study of CD38 expression. Its high specificity, sensitivity, and compatibility make it an essential component in flow cytometry-based investigations, contributing to a better understanding of CD38-related diseases and potential therapeutic interventions.
View full details